RC
DMIIU

Rangeley Capital’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Rangeley Capital’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
32,551
-23,061
-41% -$233K 0.3% 85
2026
Q1 		$327K Buy
55,612
+23,061
+71% +$232K 0.32% 67
2025
Q4 		$326K Buy
+32,551
New +$326K 0.27% 70

Other funds holding DMIIU

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rangeley Capital's DMIIU Position: Q2 2026 in Review

Rangeley Capital reduced its Drugs Made In America Acquisition II Corp Unit (DMIIU) stake by 41% in Q2 2026, selling an estimated $233K and leaving 32,551 shares worth $331K. The position accounts for 0.3% of the portfolio, ranked #85.

Rangeley Capital first reported a position in DMIIU in Q4 2025 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold DMIIU as of Q2 2026.

  • Rangeley Capital held 32,551 shares of Drugs Made In America Acquisition II Corp Unit worth $331K as of Q2 2026.
  • Rangeley Capital sold 23,061 Drugs Made In America Acquisition II Corp Unit shares in Q2 2026, an estimated $233K.
  • Drugs Made In America Acquisition II Corp Unit made up 0.3% of Rangeley Capital's portfolio in Q2 2026, its #85 holding.
  • Rangeley Capital first reported a position in Drugs Made In America Acquisition II Corp Unit in Q4 2025 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.